Jasper shows ‘good responses’ for briquilimab in CIndU, says Stifel

After Jasper Therapeutics (JSPR) reported preliminary data from the company’s ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria or symptomatic dermographism, the two most prevalent sub types of CIndU, Stifel says 120mg briquilimab showed “good responses,” but thinks the stock debate will focus on the serum tryptase signal, which wasn’t depleted to the same extent as Celldex’s (CLDX) barzolvolimab at higher dose. The firm, which thinks today’s data imply that a higher dose should “at least” support a Q8W regimen, and is “bullish” into CSU data due January 6 showcasing both 180mg and 240mg doses, keeps a Buy rating and $80 price target on Jasper shares.